SPBC1604.12 Antibody

What is SPBC1604.12 and why is it studied in fission yeast research?

SPBC1604.12 is a protein identified in Schizosaccharomyces pombe (strain 972 / ATCC 24843), commonly known as fission yeast. This protein is cataloged with Uniprot identification number O94378 . Fission yeast serves as an excellent model organism for eukaryotic cell biology research due to its relatively simple genome and conserved cellular processes. The study of specific proteins like SPBC1604.12 through antibody detection helps researchers understand fundamental cellular mechanisms that may be conserved in higher eukaryotes.

While the specific function of SPBC1604.12 is not fully characterized in the literature, fission yeast proteins are often studied for their roles in critical cellular processes such as cell division, DNA replication, chromatin organization, and stress responses. Antibodies against these proteins enable visualization of localization, quantification of expression levels, and analysis of protein-protein interactions.

How do I validate the specificity of a SPBC1604.12 antibody for my research?

Validating antibody specificity is crucial for obtaining reliable research results. For SPBC1604.12 antibody, consider implementing the following methodological approach:

• Western blotting with controls:

  • Use wild-type S. pombe lysate alongside a SPBC1604.12 deletion strain

  • Include recombinant SPBC1604.12 protein as a positive control

  • Check for a single band of the expected molecular weight

• Proteome array testing:

  • Consider screening against a yeast proteome array to identify potential cross-reactivity

  • This approach allows simultaneous screening against thousands of proteins

• Immunoprecipitation followed by mass spectrometry:

  • Perform IP with the antibody and analyze pulled-down proteins

  • The major protein identified should be SPBC1604.12

• Epitope mapping:

  • Determine the specific amino acid sequence recognized by the antibody

  • This helps predict potential cross-reactivity with related proteins

Research has shown that even highly specific antibodies may cross-react with unexpected proteins. In one study analyzing 11 antibodies against approximately 5,000 different yeast proteins, researchers found varying degrees of cross-reactivity that could not be predicted based solely on primary sequence alignment .

What are the optimal techniques for using SPBC1604.12 antibody in immunofluorescence studies?

When using SPBC1604.12 antibody for immunofluorescence in fission yeast, consider these methodological approaches:

Fixation and Permeabilization Protocol:

• Harvest cells in mid-log phase (OD₆₀₀ = 0.5-0.8)

• Fix with 3.7% formaldehyde for 30 minutes at room temperature

• Wash cells 3× with PEM buffer (100 mM PIPES, 1 mM EGTA, 1 mM MgSO₄, pH 6.9)

• Digest cell walls with Zymolyase-100T (1 mg/ml) for 30 minutes at 37°C

• Permeabilize with 1% Triton X-100 for 5 minutes

Antibody Incubation Strategy:

• Block with 5% BSA in PEMBAL buffer for 1 hour

• Incubate with primary SPBC1604.12 antibody (1:100-1:500 dilution) overnight at 4°C

• Wash 5× with PEMBAL

• Incubate with fluorophore-conjugated secondary antibody (1:500) for 2 hours

• Counterstain with DAPI (1 μg/ml) to visualize nuclei

Controls and Validation:

• Include a negative control omitting primary antibody

• Use a strain with tagged SPBC1604.12 (e.g., GFP-tagged) for co-localization studies

• When possible, include a SPBC1604.12 deletion strain

Similar protocols have been effectively used for visualization of fission yeast proteins like Scm3, which localizes to centromeres and can be observed as a single nuclear focus in most cells when properly stained .

How can I determine if post-translational modifications affect recognition of SPBC1604.12 by my antibody?

Post-translational modifications (PTMs) can significantly impact antibody recognition. To assess their influence on SPBC1604.12 antibody binding:

Experimental Approach:

• Phosphatase Treatment Test:

  • Split your lysate into two portions

  • Treat one with lambda phosphatase

  • Compare antibody binding by Western blot

  • Shift in band pattern or intensity suggests phosphorylation affects recognition

• 2D Gel Electrophoresis:

  • Separate proteins by both isoelectric point and molecular weight

  • Perform Western blotting

  • Multiple spots at the expected molecular weight indicate PTMs

• Recombinant Protein Analysis:

  • Express recombinant SPBC1604.12 with and without common PTMs

  • Compare antibody binding affinity using methods like:

    • ELISA with different protein forms (EC₅₀ comparison)

    • Surface Plasmon Resonance for binding kinetics

  • This approach is similar to methods used to study SepSecS-specific antibodies, where researchers produced four combinations of mutated and germline chains to assess binding differences

• Mass Spectrometry Validation:

  • Immunoprecipitate SPBC1604.12 from cells

  • Analyze by LC-MS/MS to identify PTMs

  • Correlate PTM presence with antibody recognition efficiency

Understanding these effects is critical as studies have shown that PTMs can dramatically alter epitope accessibility, particularly in cases where antibodies recognize conformational epitopes.

How can I develop a custom monoclonal antibody against SPBC1604.12 with improved specificity?

Developing a custom monoclonal antibody against SPBC1604.12 requires a strategic approach:

Antigen Design Strategy:

• Epitope Selection:

  • Perform computational analysis to identify unique regions of SPBC1604.12

  • Avoid regions with high homology to other proteins

  • Consider using a combination of:

    • N-terminal or C-terminal peptides (15-25 amino acids)

    • Recombinant protein domains

    • Full-length protein expressed in eukaryotic system

• Immunization and Hybridoma Generation:

  • Use 2-3 different antigens for parallel immunization

  • Screen hybridoma supernatants against both the immunogen and full-length protein

  • Implement counter-screening against related proteins to eliminate cross-reactive clones

• Comprehensive Validation:

  • Test clone specificity using Western blot against yeast lysates

  • Verify performance in multiple applications (WB, IP, IF, ChIP)

  • Consider epitope mapping to define the exact binding site

Advanced Screening Methods:

The comprehensive screening approach developed for SepSecS-specific antibodies provides an excellent model. Researchers quantified binding curves for all mAbs from which the EC₅₀ was calculated, with most high-affinity antibodies showing EC₅₀ values between 1-10 ng/mL . Similar quantitative screening can identify the highest affinity SPBC1604.12 antibodies.

Recombinant antibody technology, as used in platforms like ZooMAb®, offers advantages for producing consistent SPBC1604.12 antibodies. These antibodies are manufactured using proprietary recombinant expression systems that ensure batch-to-batch reproducibility and can be engineered for specific applications .

What approaches can resolve contradictory results obtained with different SPBC1604.12 antibody clones?

When different antibody clones against SPBC1604.12 yield contradictory results, systematic troubleshooting is essential:

Root Cause Analysis:

• Epitope Mapping:

  • Determine the binding sites of each antibody

  • Different epitopes may be differentially accessible in various experimental conditions

  • Some epitopes may be masked by protein-protein interactions

• Binding Characteristic Comparison:

  • Compare affinity constants (KD) using surface plasmon resonance

  • Determine on/off rates which may affect results in different applications

  • Assess whether antibodies recognize native or denatured forms differently

• Specificity Profiling:

  • Test each antibody against proteome arrays to identify potential cross-reactivity

  • Perform immunoprecipitation followed by mass spectrometry to identify all proteins captured

  • Create competition assays between antibodies to determine if they recognize the same epitope

Resolution Strategy:

Studies of SepSecS-specific antibodies demonstrated that competition experiments could reveal distinct binding regions, with 12 monoclonal antibodies binding to 3 different regions on the target protein . Similar approaches can help resolve which SPBC1604.12 antibody provides the most accurate results for your specific research question.

How do I optimize Western blotting protocols specifically for SPBC1604.12 detection?

For optimal Western blot detection of SPBC1604.12:

Sample Preparation Optimization:

• Extract proteins using a method that preserves protein integrity:

  • Glass bead lysis in buffer containing 50 mM Tris-HCl pH 7.5, 150 mM NaCl, 0.1% NP-40, 10% glycerol

  • Include protease inhibitors, phosphatase inhibitors if phosphorylation is relevant

  • Consider denaturing conditions (8M urea) if protein is difficult to extract

Gel Electrophoresis and Transfer Parameters:

• Select appropriate percentage acrylamide gel based on SPBC1604.12 molecular weight

• Use wet transfer for optimal results: 100V for 1 hour or 30V overnight at 4°C

• Consider transfer buffer optimization (methanol percentage may affect transfer efficiency)

Antibody Incubation Protocol:

• Block membrane with 5% non-fat milk or 3% BSA in TBS-T for 1 hour

• Use optimized antibody dilution (typically start with 1:1000 and adjust)

• Incubate primary antibody overnight at 4°C for best signal-to-noise ratio

• Use TBS-T with 0.1% Tween-20 for washes (5 × 5 minutes)

• Optimize secondary antibody concentration (typically 1:5000 to 1:20000)

Signal Development Strategy:

• For low abundance proteins, use high-sensitivity ECL substrates

• Consider fluorescent secondary antibodies for quantitative analysis

• Optimize exposure times to prevent saturation when quantifying

Troubleshooting Common Issues:

What are the key considerations for quantitatively comparing SPBC1604.12 levels across different experimental conditions?

For quantitative comparison of SPBC1604.12 across conditions:

Sample Normalization Strategy:

• Use total protein normalization rather than single housekeeping proteins

  • Stain membranes with Ponceau S or SYPRO Ruby before immunoblotting

  • Consider technologies like Stain-Free gels for total protein quantification

• When using loading controls, select appropriate reference proteins that remain stable under your experimental conditions

Quantification Methodology:

• Use fluorescent secondary antibodies rather than chemiluminescence for wider linear range

• Capture multiple exposures if using chemiluminescence to ensure signals are within linear range

• Apply appropriate software tools for densitometry analysis

• Calculate relative quantities using standard curves when possible

Technical and Biological Replicates:

• Perform at least three biological replicates

• Include technical replicates on each blot

• Consider running all samples on the same blot when possible to minimize inter-blot variation

Statistical Analysis:

• Test for normality of data distribution

• Apply appropriate statistical tests (t-test for two conditions, ANOVA for multiple conditions)

• Report standard deviation or standard error of mean

Similar quantitative approaches have been used successfully in studies of antibody binding characteristics, where researchers quantified binding curves from multiple monoclonal antibodies and calculated EC₅₀ values to compare their relative affinities .

How can I mitigate batch-to-batch variability when using commercial SPBC1604.12 antibodies?

Mitigating batch-to-batch variability is crucial for experimental reproducibility:

Proactive Mitigation Strategies:

• Lot Testing and Validation:

  • Request multiple vials from the same lot for long-term studies

  • Validate each new lot against your previous lot using identical samples

  • Create and maintain a reference sample set for comparison

• Standard Operating Procedure Development:

  • Document optimal dilutions and conditions for each application

  • Create detailed protocols specifying exact blocking reagents and incubation times

  • Standardize image acquisition parameters for consistent analysis

• Consider Recombinant Antibody Alternatives:

  • Recombinant antibodies like ZooMAbs offer superior batch-to-batch consistency

  • These are produced using proprietary recombinant expression systems rather than hybridoma cells

  • Manufacturing in defined cell culture systems eliminates variability inherent in animal-derived antibodies

Performance Comparison Table:

Research has shown that recombinant antibody technology enables production of antibodies with consistent performance characteristics, making them increasingly valuable for quantitative research applications where reproducibility is paramount .

How can I use SPBC1604.12 antibody to study protein-protein interactions in fission yeast?

SPBC1604.12 antibody can be employed in multiple approaches to study protein-protein interactions:

Co-Immunoprecipitation Protocol:

• Prepare cell lysate under non-denaturing conditions

  • 50 mM HEPES pH 7.5, 150 mM NaCl, 0.1% NP-40, 1 mM EDTA, 1 mM DTT

  • Include protease inhibitors and phosphatase inhibitors

• Pre-clear lysate with Protein A/G beads to reduce non-specific binding

• Incubate with SPBC1604.12 antibody (2-5 μg) overnight at 4°C

• Add Protein A/G beads and incubate for 2-3 hours

• Wash stringently (at least 5 times) to remove non-specific interactions

• Elute proteins and analyze by mass spectrometry or Western blotting

Proximity Ligation Assay (PLA):

• Fix cells and permeabilize as for standard immunofluorescence

• Incubate with SPBC1604.12 antibody and antibody against putative interacting protein

• Use PLA probes conjugated to appropriate secondary antibodies

• Perform ligation and amplification according to manufacturer's protocol

• Analyze fluorescent signal indicating proximity (<40 nm) between proteins

ChIP-reChIP for Protein Co-localization:
If SPBC1604.12 interacts with chromatin-associated proteins:

• Perform standard ChIP with SPBC1604.12 antibody

• Elute under non-denaturing conditions

• Perform second ChIP with antibody against suspected interacting protein

• Analyze overlapping binding sites by qPCR or sequencing

Similar approaches have been successfully applied to study interactions between fission yeast proteins, as demonstrated in research on Scm3, which was shown to interact with Cnp1 using both yeast two-hybrid and co-immunoprecipitation methods .

What are the best approaches for troubleshooting weak or inconsistent signals with SPBC1604.12 antibody?

When facing weak or inconsistent signals with SPBC1604.12 antibody:

Systematic Troubleshooting Approach:

• Antibody Validation:

  • Confirm antibody viability with dot blot of recombinant protein

  • Test alternative antibody lots or sources

  • Verify storage conditions (avoid repeated freeze-thaw cycles)

• Sample Preparation Optimization:

  • Test different lysis methods (mechanical disruption, detergent-based)

  • Adjust buffer composition (pH, salt concentration, detergent type)

  • Check for presence of interfering compounds or protein modifications

• Protocol Parameter Adjustment:

  • Increase antibody concentration or incubation time

  • Reduce washing stringency initially to determine if signal is being lost

  • Test different blocking agents (BSA vs. milk vs. commercial blockers)

• Signal Enhancement Strategies:

  • Use signal amplification systems (TSA, polymer detection)

  • For low abundance proteins, consider enrichment by immunoprecipitation before detection

  • In microscopy applications, use high-sensitivity cameras and optimize exposure settings

Methodical Protocol Modification Matrix:

These approaches have proven effective in optimizing detection conditions for various antibodies, including those used in characterization of autoimmune antibodies where detection sensitivity was crucial for accurate diagnosis .

How can I use SPBC1604.12 antibody to investigate protein localization changes during the cell cycle?

To investigate SPBC1604.12 localization changes throughout the cell cycle:

Time-Course Experimental Design:

• Cell Synchronization Options:

  • Nitrogen starvation and release

  • Hydroxyurea block and release

  • cdc25-22 temperature-sensitive mutant arrest and release

  • Lactose gradient centrifugation for size-based separation

• Fixed-Cell Time-Course Protocol:

  • Collect samples at 15-20 minute intervals after synchronization

  • Fix with 3.7% formaldehyde

  • Process for immunofluorescence with SPBC1604.12 antibody

  • Co-stain with cell cycle markers (septum with Calcofluor, DNA with DAPI)

• Live-Cell Imaging Alternative:

  • If SPBC1604.12 antibody performs poorly in fixed cells, consider:

    • Creating a GFP-tagged SPBC1604.12 strain

    • Verifying tag doesn't disrupt function

    • Using time-lapse microscopy to track localization

• Quantitative Analysis Methods:

  • Measure signal intensity at different cellular locations

  • Track changes in localization pattern relative to cell cycle markers

  • Apply statistical analysis to determine significance of changes

A similar approach was used to characterize the dynamic localization of Scm3 protein in fission yeast, revealing that it associates with centromeres in a cell cycle-regulated manner. Researchers used both fixed-cell immunofluorescence and live-cell imaging with fluorescently tagged proteins to demonstrate that Scm3 localization changes during mitosis, with its presence at centromeres decreasing during metaphase and reappearing in anaphase .

Image Analysis Parameters:

• Quantify fluorescence intensity at different cellular locations

• Track changes in size and shape of protein foci

• Correlate localization changes with cell cycle progression markers

• Create kymographs for dynamic visualization of changes over time

This methodical approach enables robust characterization of protein dynamics throughout the cell cycle, revealing important insights into protein function.

How can CRISPR-Cas9 genome editing be combined with SPBC1604.12 antibody studies to advance functional understanding?

CRISPR-Cas9 genome editing offers powerful approaches to enhance SPBC1604.12 antibody studies:

Integrated Research Strategies:

• Epitope Tagging at Endogenous Locus:

  • Design CRISPR strategy to add small epitope tags (FLAG, HA, V5) to SPBC1604.12

  • Compare antibody detection of native protein vs. tagged protein

  • Use dual detection (anti-tag and anti-SPBC1604.12) to validate antibody specificity

• Domain-Specific Function Analysis:

  • Create targeted deletions of specific SPBC1604.12 domains

  • Use antibody to assess remaining protein expression and localization

  • Map functional domains by correlating antibody detection with phenotypic changes

• Promoter Modification for Expression Studies:

  • Replace native promoter with regulatable promoter (nmt1)

  • Use antibody to quantify expression levels under different conditions

  • Correlate protein abundance with phenotypic outcomes

• Systematic Mutation Analysis:

  • Create point mutations at predicted functional sites

  • Use antibody to confirm expression of mutant proteins

  • Assess changes in localization, interactions, or stability

Methodological Considerations for CRISPR in S. pombe:

• Design guides targeting unique sequences in SPBC1604.12

• Use homology-directed repair with ~500 bp homology arms

• Include selectable marker (ura4+) for efficient screening

• Verify edits by sequencing and Western blotting with SPBC1604.12 antibody

This integrated approach has been successfully applied in studies of various fission yeast proteins, enabling precise correlation between protein function and localization.

What are the advantages of developing nanobodies against SPBC1604.12 compared to conventional antibodies?

Nanobodies offer several advantages over conventional antibodies for SPBC1604.12 research:

Comparative Advantages:

• Size and Penetration:

  • Nanobodies (~15 kDa) are substantially smaller than conventional antibodies (~150 kDa)

  • Improved penetration in fixed yeast cells with intact cell walls

  • Better access to sterically hindered epitopes in protein complexes

• Live-Cell Applications:

  • Nanobodies can be expressed intracellularly as "intrabodies"

  • Enable real-time tracking of SPBC1604.12 dynamics in living cells

  • Can be fused to degradation tags for acute protein depletion studies

• Epitope Recognition:

  • Often recognize conformational epitopes not accessible to conventional antibodies

  • Can access clefts and active sites due to smaller size

  • Single-domain structure simplifies engineering for specific applications

• Production Advantages:

  • Recombinant production in bacteria or yeast

  • Higher stability and resistance to pH and temperature

  • Consistent performance without batch-to-batch variation

Application-Specific Considerations:

This technology represents an emerging frontier in protein research tools, offering complementary approaches to conventional antibodies with distinct advantages for certain applications.